OPKO submits IND to initiate a phase 2a trial to treat hemophilia
OPKO Health announced submission of an Investigational New Drug Application to the FDA to conduct a Phase 2a study of OPKO's long-acting version of coagulation Factor VIIa (Factor VIIa-CTP) for treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX. January 30, 2015